Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Puyouheng (pucotenlimab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

HanX Biopharma, Lepu Med, Taizhou Hanzhong Biopharma

Drug class:

PD1 inhibitor

Related drugs:

‹

pembrolizumab (726)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab (84)

dostarlimab-gxly (42)

cemiplimab-rwlc (29)

zimberelimab (20)

cadonilimab (10)

serplulimab (6)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab (4)

geptanolimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

PD-1 knockout engineered T cells (0)

PF-07209960 (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

›

MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	pucotenlimab Sensitive: C2 – Inclusion Criteria pucotenlimab Sensitive : C2	pucotenlimab Sensitive: C2 – Inclusion Criteria pucotenlimab Sensitive : C2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pucotenlimab Sensitive: C2 – Inclusion Criteria pucotenlimab Sensitive : C2	pucotenlimab Sensitive: C2 – Inclusion Criteria pucotenlimab Sensitive : C2
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
MSI-H/dMMR + TMB-H	Solid Tumor	MSI-H/dMMR + TMB-H	Solid Tumor	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
MSI-H/dMMR + KMT2D mutation	Solid Tumor	MSI-H/dMMR + KMT2D mutation	Solid Tumor	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
VEGFA-L	Melanoma	VEGFA-L	Melanoma	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
TNFA-L	Melanoma	TNFA-L	Melanoma	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
CCL2 elevation	Melanoma	CCL2 elevation	Melanoma	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
CCL11 elevation	Melanoma	CCL11 elevation	Melanoma	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3